DSM’s Pharma Business Reports Weak Results in First Quarter

DSM says that the performance of the company’s pharmaceutical business in the first quarter of 2012 remained weak, although first signs of improvement are visible. The pharmaceutical business reported a 7% rise in first-quarter sales, compared with the year-ago period, to €175 million ($227 million). The business reported an Ebit loss of €8 million in the first quarter compared with an Ebit loss of €10 million in the year-ago period. DSM’s pharma business comprises DSM Pharmaceutical Products and DSM Sinochem Pharmaceuticals, the former...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers